Marijuana Problem Scale

Submitted by administrator on
Abbreviation
MPS
Description

This 19-item assessment helps the client identify areas in his or her life affected by marijuana use. Items represent the potential negative effects of marijuana on social relationships, self-esteem, motivation and productivity, work and finances, physical health, memory impairment, and legal problems. The items were chosen based on existing self-report drug abuse severity measures and on data from people who sought treatment for marijuana use. The client responds to each item by indicating whether he or she experienced a particular problem related to marijuana use in the past month (0=not a problem, 1=a minor problem, 2=a serious problem).

Category
Substance Use
Subcategory
Drugs

Marijuana Craving Questionnaire

Submitted by administrator on
Abbreviation
MCQ
Description

The 45-item MCQ is a multi-dimensional questionnaire that assesses marijuana craving. It is based on the the Cocaine Craving Questionnaire (see "Related Instruments" below) and uses items that touch on four specific constructs characterizing craving for marijuana: (1) compulsivity, an inability to control marijuana use; (2) emotionality, use of marijuana in anticipation of relief from withdrawal or negative mood; (3) expectancy, anticipation of positive outcomes from smoking marijuana; and (4) purposefulness, intention and planning to use marijuana for positive outcomes. Each item is rated on a seven-point Likert-type scale ranging from "strongly disagree" to "strongly agree."

Category
Substance Use
Subcategory
Drugs

Cannabis Withdrawal Scale

Submitted by administrator on
Abbreviation
CWS
Description

The Cannabis Withdrawal Scale (CWS, Allsop, 2011) is an assessment of cannabis-related symptoms experienced over the last 24 hours, rating the negative impact on a scale of 0 (not at all) to 10 (extremely).

Category
Substance Use
Subcategory
Drugs
Division
HEAL Study
Investigator(s)
Title
Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment (ACCENT)
Short Description
The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).
Release Date
Jul 13, 2018
Description

The primary objective of this Phase 3 study is to evaluate the impact of N-Acetylcysteine (NAC) 1200 mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50). The primary outcome measure will be the odds of negative weekly urine cannabinoid tests during active treatment. Primary analysis will be based on an intent-to-treat evaluation of all participants randomized into the study, with missing urine specimens coded as missing and assumed to be positive. Sensitivity analyses will be performed to determine how other procedures for missing data affect results.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents